公开(公告)号：US10588670B2

公开(公告)日：2020-03-17

申请号：US16376893

申请日：2019-04-05

Applicant: MUSC Foundation for Research Development

Inventor： Barton L. Sachs

IPC: A61B17/56 ,  A61B17/58 ,  A61B17/80 ,  A61F2/30 ,  A61B17/70 ,  A61F2/44 ,  A61B17/86 ,  A61F2/46 ,  A61B17/68 ,  A61F2/28

Abstract: Anterior spinal implant devices for reducing spinal malalignment and associated systems and methods are disclosed herein. A spinal implant system configured in accordance with embodiments of the present technology can include, for example, a first vertebral support implanted at an anterior region of a first vertebra of a patient, a second vertebral support implanted at an anterior region of a second vertebra inferior to the first vertebra, and an alignment system configured to be releasably coupled to the first and second vertebral supports. The first and second vertebral supports can extend into and interlock with each other within an interbody space between the first and second vertebrae when the first and second vertebral supports are aligned. The alignment system is configured to reduce angular, vertical, and linear malalignment of the first and second vertebrae relative to each other.

公开(公告)号：US10456400B2

公开(公告)日：2019-10-29

申请号：US15307966

申请日：2015-05-15

Applicant: MUSC FOUNDATION FOR RESEARCH DEVELOPMENT

Inventor： Christopher C. Lindsey ,  Craig C. Beeson

IPC: A61K31/519 ,  C07D471/14

Abstract: In some aspects, the present invention relates to aza-ellipticine compounds of the formula: wherein the variables are as defined herein. The application also provides novel methods of preparing aza-ellipticine compounds, methods of using the compounds, and pharmaceutical compositions thereof.

公开(公告)号：US20190322984A1

公开(公告)日：2019-10-24

申请号：US16448208

申请日：2019-06-21

Applicant: MUSC FOUNDATION FOR RESEARCH DEVELOPMENT

Inventor： Mark RUBINSTEIN ,  David COLE

IPC: C12N5/0783 ,  C07K14/715 ,  A61K38/20 ,  A61K38/17 ,  C12N15/85 ,  C07K14/705 ,  A61K35/17

Abstract: Cells, such a T-cells, are provided that comprise cytokine receptors having increased activity in response to their ligand. For example, cell can comprise IL-2 and/or IL-15 receptors having increased surface expression or signaling activity. Cells of the embodiments have a significant growth advantage in the presence of cytokines and can be used, e.g., for enhanced adoptive cell transfer therapies.

公开(公告)号：US10441322B2

公开(公告)日：2019-10-15

申请号：US16168106

申请日：2018-10-23

Applicant: MUSC Foundation for Research Development

Inventor： Barton L. Sachs ,  Trevor James Langley ,  Fabiano Pace ,  Alexandra Kathryn Wells ,  Carolyn Chlebek ,  Christine Marie Perrone ,  Cara Elizabeth Yocum ,  Joshua Murphy Peterson

IPC: A61B17/70 ,  A61F2/44 ,  A61B17/86 ,  A61F2/46 ,  A61B17/56 ,  A61B17/68 ,  A61F2/28 ,  A61F2/30

Abstract: Anterior spinal implant devices for reducing spinal malalignment and associated systems and methods are disclosed herein. A spinal implant system configured in accordance with embodiments of the present technology can include, for example, a first vertebral support implanted at an anterior region of a first vertebra of a patient, a second vertebral support implanted at an anterior region of a second vertebra inferior to the first vertebra, and an alignment system configured to be releasably coupled to the first and second vertebral supports. The first and second vertebral supports can extend into and interlock with each other within an interbody space between the first and second vertebrae when the first and second vertebral supports are aligned. The alignment system is configured to reduce angular, vertical, and linear malalignment of the first and second vertebrae relative to each other.

公开(公告)号：US20190301029A1

公开(公告)日：2019-10-03

申请号：US16346181

申请日：2017-11-03

Applicant: MUSC FOUNDATION FOR RESEARCH DEVELOPMENT

Inventor： Harold D. MAY ,  Edward V. LABELLE

IPC: C25B3/04 ,  C25B9/06

Abstract: In some aspects, the present disclosure provides a method of bioelectric production of organic compounds such as acetate. In further aspects, the present disclosure also provides methods of producing a hydrocarbon based fuel using C02 as the carbon source.

公开(公告)号：US10385128B2

公开(公告)日：2019-08-20

申请号：US14972698

申请日：2015-12-17

Applicant: MUSC Foundation for Research Development

Inventor： Natalie Sutkowski ,  Daniel Fernandes ,  Brian Hoel ,  Semyon Rubinchik

IPC: A61K39/395 ,  C07K16/28 ,  C07K16/18 ,  C07K16/30 ,  A61K47/68

Abstract: The present invention provides for methods of producing human monoclonal antibodies to human nucleolin, cells producing such antibodies, and the antibodies themselves. Also provided are methods of using the antibodies in diagnosing and treating malignant and non-malignant diseases wherein cells that express nucleolin on the cell surface contribute to the pathophysiology of the disease.

公开(公告)号：US10377988B2

公开(公告)日：2019-08-13

申请号：US15533103

申请日：2016-01-22

Applicant: MUSC FOUNDATION FOR RESEARCH DEVELOPMENT

Inventor： Mark Rubinstein ,  David Cole

IPC: C12N5/0783 ,  A61K35/17 ,  A61K38/17 ,  A61K38/20 ,  C07K14/715 ,  C12N15/85 ,  C07K14/705

Abstract: Cells, such a T-cells, are provided that comprise cytokine receptors having increased activity in response to their ligand. For example, cell can comprise IL-2 and/or IL-15 receptors having increased surface expression or signaling activity. Cells of the embodiments have a significant growth advantage in the presence of cytokines and can be used, e.g., for enhanced adoptive cell transfer therapies.

公开(公告)号：US10370328B2

公开(公告)日：2019-08-06

申请号：US15565820

申请日：2016-04-28

Applicant: MUSC FOUNDATION FOR RESEARCH DEVELOPMENT ,  U.S. DEPARTMENT OF VETERANS AFFAIRS

Inventor： Craig C. Beeson ,  Christopher C. Lindsey ,  Baerbel Rohrer ,  Yuri Karl Peterson

IPC: C07D209/38 ,  C07D401/06 ,  C07D403/06 ,  C07D209/36 ,  C07D403/12 ,  C07D401/14 ,  C07D401/12 ,  C07D403/14 ,  C07D405/06 ,  C07D413/06 ,  C07D498/04 ,  A61P27/02 ,  C07D209/34 ,  C07D405/12 ,  C07F9/572

Abstract: Provided herein are compounds of the formula (I) as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of degenerative diseases and disorders.

公开(公告)号：US20190127483A1

公开(公告)日：2019-05-02

申请号：US16089498

申请日：2017-03-30

Applicant: MUSC FOUNDATION FOR RESEARCH DEVELOPMENT

Inventor： Zihai LI

IPC: C07K16/34 ,  A61K31/675 ,  C07K16/28 ,  A61K31/7076 ,  A61K9/00 ,  A61P35/00 ,  C07K16/30

Abstract: Isolated or recombinant monoclonal antibodies that bind to GARP are provided. In some cases, antibodies of the embodiments can be used for the detection, diagnosis and/or therapeutic treatment of human diseases, such as cancer. Further provided herein are methods and compositions for treating cancer in an individual comprising administering to the individual an effective amount of an anti-platelet agent and a T cell therapy.

公开(公告)号：US20190125796A1

公开(公告)日：2019-05-02

申请号：US16095791

申请日：2017-04-28

Applicant: MUSC Foundation for Research Development

Inventor： Shikhar Mehrotra ,  Michael I. Nishimura ,  Pravin Kesarwani ,  Shilpak Chatterjee

IPC: A61K35/17 ,  C12N5/0783 ,  A61P35/00 ,  A61K38/20 ,  A61K38/06 ,  A61K31/381 ,  A61K31/401 ,  A61K38/43

Abstract: The present invention relates to an adoptive T cell therapy using cells generated by genetically or biochemically reprogramming T cells to produce T memory stem cells (Tscm) that persist longer in vivo and are superior anti-tumor effector cells.